Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 August 2025, Traws Pharma, Inc. has moved from a grade of does not qualify to attractive, indicating a significant improvement in its valuation outlook. The company appears to be undervalued, particularly when considering its low P/E ratio of 0, an EV to EBIT ratio of 0.14, and a remarkable ROE of 939.05%.
In comparison to its peers, Traws Pharma's valuation metrics stand out, especially against Catalyst Biosciences, Inc., which is considered expensive with a P/E of 110.04, and Elutia, Inc., which has a risky valuation with a P/E of -2.83. Despite Traws Pharma's attractive valuation, its recent stock performance has been challenging, with a year-to-date return of -76.80%, significantly underperforming the S&P 500's return of 12.22% over the same period.